News

StockStory.org on MSN9h
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s ...
Investing Snacks3h
Bristol-Myers Squibb Bets Big on Schizophrenia Drug
Jim Cramer, a stalwart of stock market commentary, recently shifted gears on Bristol-Myers Squibb, pegging his hopes on their ...
The Daily Reflector16h
Ellis George LLP: CA Court of Appeal Upholds $5 Million Jury Verdict Against Bristol-Meyers-Squibb-owned Impact Biomedicines
Dr. Brewer, chair of the neurology department at UC San Diego, was represented by Christopher W. Arledge and Courtney L. Mitchell, both of Ellis George LLP, and Peter Afrasiabi of One LLP.
Investing Snacks3h
Pfizer’s Investment Shifts Split the Market in Two!
In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...